RxDoctor Payments Data

William Bedingfield, MD

Internal Medicine · Clemson, SCNPI 1598764524

Payments from drug & device makers

$7,299in general payments, 2019–2025

Across 445 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$551
  • Teva Pharmaceuticals USA, Inc.$508
  • Pfizer$487
  • Lundbeck LLC$308
  • plus $3K from 53 others

What the payments were for

  • Speaking & faculty fees$140%
  • Food & beverage$7,273100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,299 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$318,805
Medicare patients
607
Services billed
6,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$116,205
OzempicSemaglutide62$69,456
MounjaroTirzepatide55$66,824
JardianceEmpagliflozin44$50,898
XareltoRivaroxaban47$30,483
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$28,548
JanuviaSitagliptin Phosphate29$28,007
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$19,213
TrulicityDulaglutide15$13,881
Duloxetine Hcl140$8,871
MyrbetriqMirabegron16$7,145
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate19$6,998
EntrestoSacubitril/Valsartan12$6,977
Atorvastatin Calcium523$5,891
Levothyroxine Sodium484$5,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Premarin$487$121,717220 claims
Lilly USA, LLCMounjaro, Trulicity$1,067$80,70570 claims
Novo NordiskOzempic$551$69,45662 claims
Boehringer IngelheimJardiance$83$50,89844 claims
Johnson & JohnsonXarelto$42$30,48347 claims
GSKTrelegy Ellipta$256$28,54844 claims
MerckJanuvia$31$28,00729 claims
NovartisEntresto$52$6,97712 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$5,453484 claims
AstraZenecaSymbicort$147$4,64220 claims
AbbVieSynthroid$1,340$4,59048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Clemson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →